CCL3 and lymphoma: In accordance with ibrutinib-sensitive cytokine production by activated lymphoma cells, the elevated blood levels of CCL3 and CCL4 in CLL patients show strong reduction upon ibrutinib treatment compared to other cytokines (Table 1) [12].